Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Prepaid Assets: 2020-2024

Historic Prepaid Assets for Apellis Pharmaceuticals (APLS) over the last 5 years, with Dec 2024 value amounting to $18.4 million.

  • Apellis Pharmaceuticals' Prepaid Assets rose 32.55% to $31.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.6 million, marking a year-over-year increase of 32.55%. This contributed to the annual value of $18.4 million for FY2024, which is 52.68% down from last year.
  • According to the latest figures from FY2024, Apellis Pharmaceuticals' Prepaid Assets is $18.4 million, which was down 52.68% from $38.8 million recorded in FY2023.
  • Apellis Pharmaceuticals' 5-year Prepaid Assets high stood at $70.7 million for FY2021, and its period low was $18.4 million during FY2024.
  • For the 3-year period, Apellis Pharmaceuticals' Prepaid Assets averaged around $31.3 million, with its median value being $36.7 million (2022).
  • In the last 5 years, Apellis Pharmaceuticals' Prepaid Assets soared by 162.95% in 2021 and then slumped by 52.68% in 2024.
  • Over the past 5 years, Apellis Pharmaceuticals' Prepaid Assets (Yearly) stood at $26.9 million in 2020, then skyrocketed by 162.95% to $70.7 million in 2021, then slumped by 48.13% to $36.7 million in 2022, then rose by 5.90% to $38.8 million in 2023, then slumped by 52.68% to $18.4 million in 2024.